Stay updated on Oral Upadacitinib in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.

Latest updates to the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page
- Check2 days agoChange DetectedThe study record appears unchanged.SummaryDifference0.1%

- Check9 days agoChange DetectedThe page now presents AbbVie’s study of upadacitinib for moderate-to-severe atopic dermatitis in Brazil, including its design, eligibility criteria, and outcome measures. The record also provides data-sharing information and indicates the study was withdrawn with actual enrollment of zero.SummaryDifference49%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide NIH notice announces updates and FAQs about its terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe revision identifier in the site footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Oral Upadacitinib in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.